MA-PRECISELY
7.12.2023 15:01:30 CET | Business Wire | Press release
Precisely, the global leader in data integrity, today announced continued momentum for its Precisely Data Integrity Suite. The company has added dozens of customers spanning data integration, data governance, and geo addressing Suite services, with nearly half of global Suite sales attributed to new customer logos. Precisely is helping companies, such as Belfius Bank, Smiley Technologies, UK Power Networks, and Vantage Towers, to quickly build trust in the data they store in modern cloud and hybrid environments. These organizations use this data in AI, advanced analytics, and other high-value, data-driven initiatives to achieve greater operational efficiencies and improved business outcomes.
“In our ongoing commitment to make data easy to discover, understand and use reliably, we are procuring the Precisely Data Integrity Suite,” said Zachary Decent, Data Governance & Quality Manager, Enterprise Data Management at UK Power Networks, providing power to a quarter of the UK’s population. “This move signifies our dedication to fostering Data Best Practice principles, leveraging this platform to offer stakeholders an enriched experience through a comprehensive data catalog, with clearly defined data responsibilities and robust quality monitoring mechanisms.”
"Smiley's Analytics Services depend on a very high level of accuracy for address validation and location data,” said Chris Raper, Chief Strategy Officer, Smiley Technologies Inc., a provider of core banking software and services for community banks and financial institutions. “Leveraging Precisely Data Integrity Suite has allowed us to seamlessly integrate these services into our overall analytics solution supporting Community Banks.”
Research and consulting firm Gartner® identified data integrity as one of four themes in its recent Hype Cycle™ research1. According to the report, “AI relies on data, and better data leads to more reliable AI solutions. Without automated support, validating massive volumes of data is impossible.”
“We chose the Precisely Data Integrity Suite because it will provide us with a strong data governance framework that enables us to leverage trusted data across our organization,” said Sascha Glomski, Manager BI & Finance Transformation, Vantage Towers. “As one of the largest operators of mobile towers in Europe, having end-to-end visibility and a better understanding of our data will help us improve operations, reduce costs, and accelerate time to market.”
In addition to customer traction, Precisely added new partner certifications for the Data Integrity Suite this year. With the Suite, organizations can natively run data integrity processes at scale within leading data cloud environments, such as AWS Redshift, Databricks, Snowflake, and more, accelerating analytics where the data resides.
“Precisely allowed us to scale our integrated data governance and data quality program in order to reach our 2025 ambitions,” said Jérôme Sandron, Head of Data Governance at Belfius Bank, a leading Belgian banking and insurance group.
With the Precisely Data Integrity Suite, businesses harness trusted data to improve customer experiences, increase revenues, reduce costs, and mitigate risk. Comprising interoperable cloud services that share a common data catalog and user experience, the Suite gives organizations confidence their data, wherever it’s stored, has maximum accuracy, consistency, and context. The Data Integrity Suite includes Data Integration, Data Quality, Data Governance, Data Observability, Geo Addressing, Spatial Analytics, and Data Enrichment services.
“The strong customer momentum for the Data Integrity Suite confirms that it is essential to deliver cloud-native data integrity processing,” said Eric Yau, Chief Operating Officer at Precisely. “There is a need for trusted data, and we’re here to solve the complexities for business and data teams alike. We have extensive expertise to provide a clear path for businesses focused on achieving faster insights and optimal efficiencies for their organizations.”
Please visit the Precisely Data Integrity Suite page for more information about data integrity and its benefits.
GARTNER and HYPE CYCLE are a registered trademarks and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
1 Gartner, Hype Cycle for Emerging Technologies in Finance, 2023, July 11, 2023, Mark McDonald
About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231207647047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom